Immunome
Immunome is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Immunome.
Immunome is a company.
Key people at Immunome.
Key people at Immunome.
Immunome, Inc. (NASDAQ: IMNM) is a clinical-stage biotechnology company developing first-in-class and best-in-class targeted cancer therapies, primarily antibody-drug conjugates (ADCs), radioligand therapies (RLTs), and other immunotherapies for oncology indications with high unmet needs.[1][3][6] It leverages proprietary platforms like Artemis™ (formerly RealMab™ and ScreenMab™) to discover novel antibodies and targets from human memory B cells and super-responder patients, addressing undruggable targets in oncology and infectious diseases.[1][2][4] The company serves cancer patients globally through its internal pipeline and potential biopharma partnerships, solving the problem of limited effective treatments for solid tumors by delivering potent anti-cancer agents directly to tumors.[1][2][3] As of early 2025, Immunome shows growth momentum with late-stage assets like varegacestat (AL102) for desmoid tumors, Phase 1 IM-1021 (ROR1 ADC), IND-cleared IM-3050 (FAP RLT), and preclinical ADCs, bolstered by strategic acquisitions like from Zentalis and Atreca.[3][5]
Immunome was founded in 2018, evolving from earlier tumor immunology efforts documented in a 2016 corporate overview under Immunome Corp., which raised an $8.5M Series A to advance platforms isolating fully human antibodies from super-responder patients.[1][4] The company originated from expertise in leveraging the human immune system—specifically RealMab™ (isolating antibodies against patient tumors) and ScreenMab™ (functional screening)—to identify antigen-antibody pairs for ADCs and CAR-T therapies.[4] Key early traction came from building a pipeline of these pairs and rapid team expansion post-Series A.[4] By 2024-2025, Immunome shifted to a clinical-stage focus under experienced leadership with track records in commercializing ADCs for lymphoma and bladder cancer, incorporating acquisitions and IND clearances for multiple programs.[3][5][6]
Immunome stands out in the competitive biotech landscape through:
Immunome rides the ADC and targeted oncology wave, a market exploding due to successes like approved ADCs for lymphoma and bladder cancer, with demand for next-gen therapies addressing solid tumor limitations in existing programs.[3][5][6] Timing aligns with 2025 IND clearances and clinical readouts amid rising investor interest in precision oncology, fueled by advances in linker/payload tech and radioligands.[3][5] Favorable forces include high unmet needs in desmoid tumors/solid cancers, biopharma partnering trends for non-dilutive capital, and Immunome's human immune-derived assets differentiating from synthetic libraries.[1][2][5] It influences the ecosystem by validating underexplored targets, enabling efficient clinical decisions, and contributing to the shift toward target-driven, multimodal oncology tools.[2][5]
Immunome is poised to advance its pipeline toward key 2025-2026 milestones, including Phase 1 data for IM-1021/IM-3050, potential varegacestat approval, and new INDs for IL-38 and preclinical ADCs, while pursuing partnerships to de-risk development.[3][5] Trends like ADC optimization, radioligand expansion, and M&A in oncology will shape its path, potentially scaling influence through commercialization or buyouts in a syndicate-backed model.[2][5] Evolving from discovery to a premier targeted oncology player, Immunome could deliver transformative therapies, tying back to its core mission of harnessing human immunology for patients facing limited options.[1][3]
